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= amino-terminal proBNP; PAC = pulmonary artery catheterization.
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Abstract
B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-
proBNP) are promising cardiac biomarkers that have recently been
shown to be of diagnostic value in decompensated heart failure,
acute coronary syndromes and other conditions resulting in
myocardial stretch and volume overload. In view of the high
prevalence of cardiac disorders in the intensive care unit, the
experience of elevated natriuretic peptide levels in the critically ill
might be of enormous diagnostic and therapeutic value. BNP and
NT-proBNP levels rise to different degrees in critical illness and may
also serve as markers of severity and prognosis in diseases beyond
acute or chronic heart failure. The diagnostic and prognostic use of
natriuretic peptides in the intensive care setting for patients with
various forms of shock could be an attractive alternative as
noninvasive markers of cardiac dysfunction that could obviate the
need for pulmonary artery catheterization in some patients.
In a recent issue of Critical Care, Januzzi and coworkers [1]
report the results of a prospective cohort study, evaluating
natriuretic peptides in various shock patients in the intensive
care unit (ICU). The authors found no correlation between
elevated levels of amino-terminal pro-BNP (NT-proBNP) and
high filling pressures among patients with shock within the
ICU, but higher values were reported to be strongly
associated with death. A low level of NT-proBNP, however,
identified low risk patients, who were less likely to benefit
from pulmonary artery catheterization (PAC). The authors
posed the question, therefore, whether NT-proBNP measure-
ments can replace the need for PAC in ICU patients.
Brain natriuretic peptide (BNP) has been shown to be a
useful cardiac biomarker for the identification of patients with
suspected heart failure [2]. Elevated serum levels have been
described in both left ventricular (LV) systolic and diastolic
dysfunction as well as in right ventricular pressure overload
states, such as pulmonary embolism, cor pulmonale and
primary pulmonary hypertension [3]. BNP and its amino-
terminal fragment NT-proBNP are markers of LV dysfunction,
and elevated levels aid in discriminating cardiac from non-
cardiac dyspnea [2]. Peptide levels also correlate with LV
filling pressures (LVFP) in patients with depressed systolic
function [4]. However, it is unclear whether BNP or NT-
proBNP correlate with pulmonary capillary wedge pressure in
a population of critically ill patients with a broad range of life-
threatening diagnoses. Many critically ill patients have clinical
and radiographic findings that cast doubt on LVFP. PAC has
been used to measure LVFP and guide patient management.
However, given its cost, complications, and evidence from
recent studies that it has either a neutral or negative effect on
ICU patient outcome, a reliable non-invasive method or
parameter for the estimation of LVFP is needed [5,6].
Patients with various forms of shock have a high mortality in
the ICU [7]. One method of evaluating patients with shock is
invasive hemodynamic monitoring with PAC. In the modern
era, however, non-invasive methods for estimating cardiac
filling pressures and hemodynamics in ICU patients with
shock, such as biomarkers capable of predicting prognosis,
are coming to light. Several studies have shown that levels of
the neurohormones BNP and NT-proBNP are increased in
patients with cardiac dysfunction and severe sepsis or septic
shock [8-12]. Moreover, these studies have shown that
NT-proBNP can serve as an early marker of prognosis in this
patient population [8,11].
Similar to previous examinations [13], Januzzi and coworkers
[1] demonstrated that elevated levels of NT-proBNP were
strongly associated with the risk of death in the ICU, and
were even stronger predictors of death than APACHE II
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scores. It is doubtful, however, whether BNP or NT-proBNP
correlate with invasively measured hemodynamic parameters,
such as pulmonary capillary wedge pressure or low cardiac
output in patients with various types of shock in the ICU
[1,14]. In agreement with the findings reported by Jannuzzi
and coworkers in the present issue of Critical Care [1],
previous investigators reported that lower levels of NT-BNP
identified patients with lower risk and better prognosis and
that they may differentiate survivors from non-survivors in the
ICU [8,11]. Thus, Januzzi and coworkers suggested that low
NT-proBNP concentrations may be useful indicators to avoid
PAC in low risk patients in the ICU.
Several mechanisms account for increased natriuretic
peptide levels in shock patients and for the observed lack of
association between natriuretic peptides and cardiac filling
pressures and hemodynamics. First, lipopolysaccharide [15]
and proinflammatory cytokines such as interleukin-1β [16]
and cardiotrophin-1 [17] up-regulate transcription of the gene
encoding BNP. Second, wall stretch can activate the Janus
kinase/signal transducer and activator of transcription (JAK/
STAT) pathway in cardiomyocytes; this activation augments
IL-6 mRNA expression and consecutively IL-6 release [18].
According to Witthaut and collegues [10], who found a
correlation between levels of natriuretic peptides and
interleukin-6 plasma levels, the upregulation of IL-6 may effect
cardiac release of natriuretic peptides. Thus, plasma levels of
natriuretic peptides are not only affected by LV function, but
also by secretion of inflammatory cytokines such as IL-6 in
ICU shock patients. However, future studies evaluating the
precise mechanisms responsible for enhanced natriuretic
peptide secretion in critically ill patients are still needed.
In critically ill patients, the use of PAC neither increases overall
mortality or days in hospital nor confers benefit. Despite almost
20 years of randomized clinical trials, a clear benefit leading to
improved survival from the use of PAC has not been proven.
The neutrality of PAC for clinical outcomes may result from the
absence of effective evidence-based treatment regimens
according to PAC information across the spectrum of critically ill
patients. Further clinical trials should lead to the establishment
of treatment protocols for the use of PAC in this patient
population. The additional measurement of NT-proBNP in
critically ill patients may provide promising decision support for
the application of PAC and may help to identify candidates who
might benefit from PAC measurements or be harmed by PAC.
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